Investor Briefing
Each year, about 200,000 U.S. cancer patients develop spinal metastases. The scans that reveal their fracture risk are already being taken. The signal simply isn’t being read. Previze.AI turns that unread signal into a repeatable, quantitative forecast, and a defensible position inside the imaging workflow oncology already runs.
1
Traction
Previze.AI spent its early years building the clinical data first, through publications, pilot deployments at academic cancer centers, and non-dilutive funding, before scaling go-to-market.
The methodology is quantitative CT-biomarker analysis, not a black-box claim. That’s what convinces clinicians to adopt it, and what will convince payers to reimburse it.
1,300+
Patients
7
Publications
3
Active pilots
$93K
Non-dilutive funding
2
Why Now
“
A 200,000-patient market already exists inside a scan that’s taken every day, and no quantitative standard of care has claimed it yet.
~200K
U.S. spinal metastasis patients / year
1 in 8
Will suffer a spinal fracture
50%
Result in inpatient admission
2×
Higher risk of death after fracture